Shanghai S.E.
03:30:00 22/05/2024 am IST
5-day change
1st Jan Change
27.5
CNY
-0.47%
-3.20%
-14.70%
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
March 31, 2021 at 01:51 pm IST
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was CNY 636.050 million compared to CNY 546.758 million a year ago. Operating income was CNY 158.714 million compared to CNY 127.774 million a year ago. Net income was CNY 151.522 million compared to CNY 123.895 million a year ago. Basic earnings per share from continuing operations was CNY 1.07 compared to CNY 0.88 a year ago.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
25/04
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
26/23/26
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.(XSSC:603896) added to S&P Global BMI Index
18/23/18
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. agreed to acquire Hangzhou Yunhe Hengli Commercial Real Estate Co., Ltd from Hangzhou Yunhe Group Construction Management Co., Ltd. for CNY 0.001 million.
13/23/13
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
26/23/26
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
27/23/27
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
03/23/03
CI
Shouxiangu Pharma Unit Secures Re-Registration Approval for Three Drugs
17/23/17
MT
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
26/22/26
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
21/22/21
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
28/22/28
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
27/22/27
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
27/21/27
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
13/21/13
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 4, 2020, has expired with 3,585,000 shares, representing 2.5% for CNY 165.08 million.
11/21/11
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
08/21/08
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
24/21/24
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
02/21/02
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
28/21/28
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
02/21/02
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
31/21/31
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
05/21/05
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. announces an Equity Buyback for 3,600,000 shares, for CNY 216 million.
04/20/04
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
27/20/27
CI
Xu Meiyun completed the acquisition of 5.99% stake in Zhejiang Shouxiangu Pharmaceutical Co., Ltd. from Zhejiang Shouxiangu Investment Management Co., Ltd.
13/20/13
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Zhejiang Shouxiangu Pharmaceutical Co Ltd is a China-based company principally engaged in the breeding, cultivation, processing and sales of traditional Chinese medicinal materials, such as the ganoderma lucidums and dendrobium officinales. The Company's main products include ganoderma lucidum spore powder, Tiepi Fengdou granule, ganoderma extract products and fresh dendrobium officinales, among others. The Company mainly operates its businesses in domestic markets through wholesaling and direct sales.
More about the company
1st Jan change
Capi.
-14.70% 75Cr +38.28% 606.58Cr -16.91% 442.34Cr +5.14% 326.2Cr -14.63% 299.8Cr -4.12% 246.77Cr +42.14% 189.42Cr -10.63% 163.06Cr -2.71% 160.21Cr -12.26% 154.35Cr
Alternative Medicine
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
ZHEJIANG SHOUXIANGU PHARMACEUTICAL CO., LTD. 
